Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: heterocyclic P3.

A series of N(alpha)-2-benzoxazolyl-alpha-amino acid-(arylaminoethyl)amides were identified as potent, selective, and noncovalent inhibitors of cathepsin S. Structure-activity relationships including strategies for modulating the selectivities among cathepsins S, K, and L, and in vivo pharmacokinetics are discussed. A X-ray structure of compound 3 bound to the active site of cathepsin S is also reported.

[1]  Yong Wang,et al.  Design and synthesis of dipeptide nitriles as reversible and potent Cathepsin S inhibitors. , 2002, Journal of medicinal chemistry.

[2]  E. Altmann,et al.  Arylaminoethyl amides as inhibitors of the cysteine protease cathepsin K-investigating P1' substituents. , 2003, Bioorganic & medicinal chemistry letters.

[3]  P. Christadoss,et al.  Cathepsin S Is Required for Murine Autoimmune Myasthenia Gravis Pathogenesis1 , 2005, The Journal of Immunology.

[4]  Munir Pirmohamed,et al.  The role of metabolic activation in drug-induced hepatotoxicity. , 2005, Annual review of pharmacology and toxicology.

[5]  Lars Karlsson,et al.  Identification of a Potent and Selective Noncovalent Cathepsin S Inhibitor , 2004, Journal of Pharmacology and Experimental Therapeutics.

[6]  R. Thurmond,et al.  Cathepsin S inhibitors as novel immunomodulators. , 2005, Current opinion in investigational drugs.

[7]  W. Jahnke,et al.  Arylaminoethyl amides as novel non-covalent cathepsin K inhibitors. , 2002, Journal of medicinal chemistry.

[8]  Traian Sulea,et al.  Specificity determinants of human cathepsin s revealed by crystal structures of complexes. , 2003, Biochemistry.

[9]  D. Spero,et al.  Cysteine protease cathepsin S as a key step in antigen presentation. , 2004, Drug news & perspectives.

[10]  A. Rudensky,et al.  Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. , 1999, Immunity.

[11]  R. Tommasi,et al.  N-arylaminonitriles as bioavailable peptidomimetic inhibitors of cathepsin B. , 2003, Bioorganic & medicinal chemistry letters.

[12]  Jennifer L. Harris,et al.  Design and synthesis of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 1. , 2005, Bioorganic & medicinal chemistry letters.

[13]  Vincent Leroy,et al.  Cathepsin S inhibitors , 2004 .

[14]  C. Bayly,et al.  Rational design of potent and selective NH-linked aryl/heteroaryl cathepsin K inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[15]  Mary Pat Beavers,et al.  Nonpeptidic, noncovalent inhibitors of the cysteine protease cathepsin S. , 2004, Journal of medicinal chemistry.

[16]  P. Young,et al.  3-[1-(2-Benzoxazolyl)hydrazino]propanenitrile derivatives: inhibitors of immune complex induced inflammation. , 1988, Journal of medicinal chemistry.